[{"volume":12,"publication_status":"published","main_file_link":[{"open_access":"1","url":"https://doi.org/10.1016/j.waojou.2019.100044"}],"oa":1,"article_number":"100044","date_published":"2019-07-29T00:00:00Z","_id":"8228","abstract":[{"lang":"eng","text":"Background: Atopics have a lower risk for malignancies, and IgE targeted to tumors is superior to IgG in fighting cancer. Whether IgE-mediated innate or adaptive immune surveillance can confer protection against tumors remains unclear.\r\nObjective: We aimed to investigate the effects of active and passive immunotherapy to the tumor-associated antigen HER-2 in three murine models differing in Epsilon-B-cell-receptor expression affecting the levels of expressed IgE.\r\nMethods: We compared the levels of several serum specific anti-HER-2 antibodies (IgE, IgG1, IgG2a, IgG2b, IgA) and the survival rates in low-IgE ΔM1M2 mice lacking the transmembrane/cytoplasmic domain of Epsilon-B-cell-receptors expressing reduced IgE levels, high-IgE KN1 mice expressing chimeric Epsilon-Gamma1-B-cell receptors with 4-6-fold elevated serum IgE levels, and wild type (WT) BALB/c. Prior engrafting mice with D2F2/E2 mammary tumors overexpressing HER-2, mice were vaccinated with HER-2 or vehicle control PBS using the Th2-adjuvant Al(OH)3 (active immunotherapy), or treated with the murine anti-HER-2 IgG1 antibody 4D5 (passive immunotherapy).\r\nResults: Overall, among the three strains of mice, HER-2 vaccination induced significantly higher levels of HER-2 specific IgE and IgG1 in high-IgE KN1, while low-IgE ΔM1M2 mice had higher IgG2a levels. HER-2 vaccination and passive immunotherapy prolonged the survival in tumor-grafted WT and low-IgE ΔM1M2 strains compared with treatment controls; active vaccination provided the highest benefit. Notably, untreated high-IgE KN1 mice displayed the longest survival of all strains, which could not be further extended by active or passive immunotherapy.\r\nConclusion: Active and passive immunotherapies prolong survival in wild type and low-IgE ΔM1M2 mice engrafted with mammary tumors. High-IgE KN1 mice have an innate survival benefit following tumor challenge."}],"issue":"7","article_processing_charge":"No","date_updated":"2021-01-12T08:17:36Z","user_id":"2DF688A6-F248-11E8-B48F-1D18A9856A87","publication_identifier":{"issn":["1939-4551"]},"article_type":"original","oa_version":"Published Version","year":"2019","quality_controlled":"1","publication":"World Allergy Organization Journal","status":"public","intvolume":"        12","publisher":"Elsevier","extern":"1","month":"07","date_created":"2020-08-10T11:50:54Z","language":[{"iso":"eng"}],"doi":"10.1016/j.waojou.2019.100044","day":"29","type":"journal_article","author":[{"first_name":"Josef","full_name":"Singer, Josef","last_name":"Singer","orcid":"0000-0002-8701-2412"},{"last_name":"Achatz-Straussberger","full_name":"Achatz-Straussberger, Gertrude","first_name":"Gertrude"},{"last_name":"Bentley-Lukschal","full_name":"Bentley-Lukschal, Anna","first_name":"Anna"},{"full_name":"Fazekas-Singer, Judit","first_name":"Judit","last_name":"Fazekas-Singer","id":"36432834-F248-11E8-B48F-1D18A9856A87","orcid":"0000-0002-8777-3502"},{"last_name":"Achatz","first_name":"Gernot","full_name":"Achatz, Gernot"},{"last_name":"Karagiannis","full_name":"Karagiannis, Sophia N.","first_name":"Sophia N."},{"last_name":"Jensen-Jarolim","full_name":"Jensen-Jarolim, Erika","first_name":"Erika"}],"citation":{"mla":"Singer, Josef, et al. “AllergoOncology: High Innate IgE Levels Are Decisive for the Survival of Cancer-Bearing Mice.” <i>World Allergy Organization Journal</i>, vol. 12, no. 7, 100044, Elsevier, 2019, doi:<a href=\"https://doi.org/10.1016/j.waojou.2019.100044\">10.1016/j.waojou.2019.100044</a>.","ista":"Singer J, Achatz-Straussberger G, Bentley-Lukschal A, Singer J, Achatz G, Karagiannis SN, Jensen-Jarolim E. 2019. AllergoOncology: High innate IgE levels are decisive for the survival of cancer-bearing mice. World Allergy Organization Journal. 12(7), 100044.","ieee":"J. Singer <i>et al.</i>, “AllergoOncology: High innate IgE levels are decisive for the survival of cancer-bearing mice,” <i>World Allergy Organization Journal</i>, vol. 12, no. 7. Elsevier, 2019.","chicago":"Singer, Josef, Gertrude Achatz-Straussberger, Anna Bentley-Lukschal, Judit Singer, Gernot Achatz, Sophia N. Karagiannis, and Erika Jensen-Jarolim. “AllergoOncology: High Innate IgE Levels Are Decisive for the Survival of Cancer-Bearing Mice.” <i>World Allergy Organization Journal</i>. Elsevier, 2019. <a href=\"https://doi.org/10.1016/j.waojou.2019.100044\">https://doi.org/10.1016/j.waojou.2019.100044</a>.","apa":"Singer, J., Achatz-Straussberger, G., Bentley-Lukschal, A., Singer, J., Achatz, G., Karagiannis, S. N., &#38; Jensen-Jarolim, E. (2019). AllergoOncology: High innate IgE levels are decisive for the survival of cancer-bearing mice. <i>World Allergy Organization Journal</i>. Elsevier. <a href=\"https://doi.org/10.1016/j.waojou.2019.100044\">https://doi.org/10.1016/j.waojou.2019.100044</a>","ama":"Singer J, Achatz-Straussberger G, Bentley-Lukschal A, et al. AllergoOncology: High innate IgE levels are decisive for the survival of cancer-bearing mice. <i>World Allergy Organization Journal</i>. 2019;12(7). doi:<a href=\"https://doi.org/10.1016/j.waojou.2019.100044\">10.1016/j.waojou.2019.100044</a>","short":"J. Singer, G. Achatz-Straussberger, A. Bentley-Lukschal, J. Singer, G. Achatz, S.N. Karagiannis, E. Jensen-Jarolim, World Allergy Organization Journal 12 (2019)."},"title":"AllergoOncology: High innate IgE levels are decisive for the survival of cancer-bearing mice"}]